PLGA-Astragalus Polysaccharide Nanovaccines Exert Therapeutic Effect in Colorectal Cancer
International Journal of Nanomedicine · 2024
DOI: 10.2147/ijn.s479334 ↗Kurz gefasst
Fachartikel in der Zeitschrift International Journal of Nanomedicine, 2024. Verfasst von Qian Cao und 8 weiteren Autor:innen. Beteiligte Einrichtung: The First School of Clinical Medicine, Ningxia Medical University, Yinchuan, 750004, People's Republic of China. Hauptthemen laut MEDLINE: Colorectal Neoplasms, Cancer Vaccines, Polysaccharides, Polylactic Acid-Polyglycolic Acid Copolymer. Die Arbeit wurde bisher 18-mal zitiert (Crossref) und nennt 20 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 3.0).
Abstract (Originalsprache)
Background
Tumor vaccines have achieved remarkable progress in treating patients with various tumors in clinical studies. Nevertheless, extensive research has also revealed that tumor vaccines are not up to expectations for the treatment of solid tumors due to their low immunogenicity. Therefore, there is an urgent need to design a tumor vaccine that can stimulate a broad anti-tumor immune response.
Methods
In this work, we developed a nanovaccine (NP-TCL@APS), which includes nanoparticles loaded with colorectal cancer tumor cell lysates (TCL) and Astragalus polysaccharides (APS) into poly (lactic-co-glycolic acid) to induce a robust innate immune response. The NP-TCL@APS was identified by transmission electron microscopy and Malvern laser particle size analyzer. The killing and immune activation effects of NP-TCL@APS were evaluated in vitro. Finally, safety and anti-tumor efficacy were evaluated in the colorectal cancer tumor-bearing mouse model.
Results
We found that NP-TCL@APS was preferentially uptaken by DC and further promoted the activation of DC in vitro. Additionally, nanoparticles codelivery of TCL and APS enhanced the antigen-specific CD8+ T cell response and suppressed the growth of tumors in mouse models with good biocompatibility.
Conclusion
We successfully prepared a nanovaccine termed NP-TCL@APS, which can promote the maturation of DC and induce strong responses by T lymphocytes to exert anti-tumor effects. The strategy proposed here is promising for generating a tumor vaccine and can be extended to various types of cancers.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- The First School of Clinical Medicine, Ningxia Medical University, Yinchuan, 750004, People's Republic of China.
- School of Inspection, Ningxia Medical University, Yinchuan, 750004, People's Republic of China.
- Institute of Medical Sciences, General Hospital of Ningxia Medical University, Yinchuan, Yinchuan, 750004, People's Republic of China.
- Traditional Chinese Medicine Hospital of Ningxia Medical University, Yinchuan, 750003, People's Republic of China.
- School of Basic Medical Sciences, Ningxia Medical University, Yinchuan, 750004, People's Republic of China.
- Department of Oncology Surgery, the First People's Hospital of Yinchuan, Yinchuan, 750004, People's Republic of China.
Zitieren
APA
Cao, Q., Zhou, R., Guo, S., Meng, K., Yang, X., Liu, M., Ma, B., Su, C., & Duan, X. (2024). PLGA-Astragalus Polysaccharide Nanovaccines Exert Therapeutic Effect in Colorectal Cancer. International Journal of Nanomedicine. https://doi.org/10.2147/ijn.s479334
Vancouver
Cao Q, Zhou R, Guo S, Meng K, Yang X, Liu M, et al. PLGA-Astragalus Polysaccharide Nanovaccines Exert Therapeutic Effect in Colorectal Cancer. International Journal of Nanomedicine. 2024. doi:10.2147/ijn.s479334
BibTeX
@article{Cao2024,
author = {Cao, Qian and Zhou, Ruijie and Guo, Songlin and Meng, Kai and Yang, Xiaojuan and Liu, Miao and Ma, Bin and Su, Chunxia and Duan, Xiangguo},
title = {PLGA-Astragalus Polysaccharide Nanovaccines Exert Therapeutic Effect in Colorectal Cancer},
journal = {International Journal of Nanomedicine},
year = {2024},
doi = {10.2147/ijn.s479334}
}
EUVIMED